George V. Mazariegos, MD, is the director of Pediatric Transplantation at Children's Hospital of Pittsburgh of UPMC. He also is director of Pediatric Transplantation at the Thomas E. Starzl Transplantation Institute and an associate professor at the University of Pittsburgh in the departments of Surgery, Anesthesiology and Critical Care Medicine.
Dr. Mazariegos specializes in the treatment of pediatric patients who have liver and/or intestinal disease that require transplantation. He also cares for children who develop acute liver failure and who may require specialized liver support therapies until they recover or until donor organs are available.
Dr. Mazariegos' research focuses on further refining immunosuppression therapy to improve transplant outcomes and quality of life. He currently is leading clinical efforts to evaluate lowering or withdrawing immunosuppression in long-term liver transplant recipients in order to maximize quality of life and minimize post-transplant complications. Dr. Mazariegos also is analyzing immunologic characteristics of patients successfully withdrawn from immunosuppression. This study, sponsored by the Immune Tolerance Network, is attempting to develop a "tolerance assay" that can be used to prospectively characterize patients who may be candidates for less immunosuppression.
Dr. Mazariegos specializes in the treatment of pediatric patients who have liver and/or intestinal disease that require transplantation. He also cares for children who develop acute liver failure and who may require specialized liver support therapies until they recover or until donor organs are available.
Dr. Mazariegos' research focuses on further refining immunosuppression therapy to improve transplant outcomes and quality of life. He currently is leading clinical efforts to evaluate lowering or withdrawing immunosuppression in long-term liver transplant recipients in order to maximize quality of life and minimize post-transplant complications. Dr. Mazariegos also is analyzing immunologic characteristics of patients successfully withdrawn from immunosuppression. This study, sponsored by the Immune Tolerance Network, is attempting to develop a "tolerance assay" that can be used to prospectively characterize patients who may be candidates for less immunosuppression.
Videos (1)
George Mazariegos, MD is associated with the following videos.
